Figure 7. Lung scaffold recellularized by LL‐37 engineered human DASCs has enhanced anti‐bacterial ability.

• A
  Anti‐Krt5 (red) and anti‐P63 (green) immunofluorescence of isolated hDASCs. Scale bar, 90 μm.
• B
  The mRNA expression levels of LL‐37 were measured by real‐time qPCR for WT‐ and LL‐37‐hDASCs. n = 5. Error bars, SEM.
• C
  H&E staining of native rat lung tissue and decellularized scaffold showed the absence of nuclei following decellularization. Scale bar, 40 μm.
• D
  Ex vivo biomimetic culture of LL‐37‐hDASCs recellularized lungs with constant media perfusion.
• E
  Direct fluorescence image showing GFP‐labeled LL‐37‐hDASCs before (left) and 7 days after (right) being engrafted onto the decellularized scaffold. Scale bar, 50 μm (right panel) and 2,000 μm (right panel).
• F
  Immunofluorescence of recellularized lung with indicated antibodies. Blue color indicates nuclear DAPI staining. Scale bar, 50 μm.
• G
  The recellularized lung by LL‐37‐hDASCs displayed growth inhibitory effect on PAO1 and Escherichia coli. Initial dose of bacteria was 2 × 10⁴ CFU. Culture duration, 24 h. n = 6. Error bars, SEM.

Data information: Statistics for graphs: unpaired two‐tailed t‐test (B) and one‐way ANOVA followed by Tukey's test (G). *P < 0.05; ***P < 0.001; ****P < 0.0001.Source data are available online for this figure.